Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Eastern Cooperative Oncology Group National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00309985 |
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen ablation therapy may stop the adrenal glands from making androgens. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether androgen ablation therapy is more effective with or without docetaxel in treating metastatic prostate cancer.
PURPOSE: This randomized phase III trial is studying androgen ablation therapy and chemotherapy to see how well they work compared to androgen ablation therapy alone in treating patients with metastatic prostate cancer.
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: docetaxel Procedure: antiandrogen therapy |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized |
Official Title: | CHAARTED: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer [CHAARTED] |
Estimated Enrollment: | 600 |
Study Start Date: | July 2006 |
Estimated Primary Completion Date: | April 2024 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm A: Experimental
Patients receive androgen deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
|
Drug: docetaxel
Given IV
Procedure: antiandrogen therapy
No information provided
|
Arm B: Active Comparator
Patients receive androgen deprivation therapy (as in arm A) alone.
|
Procedure: antiandrogen therapy
No information provided
|
OBJECTIVES:
Primary
Secondary
Tertiary
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (≥ 70 vs < 70), ECOG performance status (0-1 vs 2), combined androgen blockade for > 30 days (yes vs no), duration of prior adjuvant hormonal therapy (> 12 months vs ≤ 12 months), concurrent bisphosphonate use (yes vs no), and volume of disease (low vs high). Patients are randomized to 1 of 2 treatment arms.
After completion of study treatment, patients are followed periodically for up to 10 years.
PROJECTED ACCRUAL: A total of 568 patients will be accrued for this study.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed prostate cancer
High-volume metastatic disease meeting any of the following criteria:
Bone metastases
On androgen deprivation therapy for < 120 days
PATIENT CHARACTERISTICS:
ECOG performance status (PS) 0-2
No prior malignancy in the past 5 years except for basal cell or squamous cell carcinoma of the skin
No active cardiac disease, including the following:
PRIOR CONCURRENT THERAPY:
Prior adjuvant or neoadjuvant hormonal therapy allowed provided the following are true:
At least 12 months since prior therapy with no evidence of disease, defined as 1 of the following:
No more than 24 months of prior therapy
Study Chair: | Christopher Sweeney, MBBS | Indiana University Melvin and Bren Simon Cancer Center |
Investigator: | David Jarrard, MD | University of Wisconsin, Madison |
Study ID Numbers: | CDR0000462099, ECOG-E3805 |
Study First Received: | March 29, 2006 |
Last Updated: | January 9, 2009 |
ClinicalTrials.gov Identifier: | NCT00309985 |
Health Authority: | Unspecified |
recurrent prostate cancer stage IV prostate cancer |
Docetaxel Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms |
Genital Diseases, Male Prostatic Neoplasms Recurrence |
Neoplasms Neoplasms by Site |